Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Adv Drug Deliv Rev. 2012 Jun 1;64(8):739-48. doi: 10.1016/j.addr.2011.06.010. Epub 2011 Jun 29.
Recent pre-clinical and clinical studies have shown that stem cell-based therapies hold tremendous promise for the treatment of human disease. Mesenchymal stem cells (MSC) are emerging as promising anti-cancer agents which have an enormous potential to be utilized to treat a number of different cancer types. MSC have inherent tumor-trophic migratory properties, which allows them to serve as vehicles for delivering effective, targeted therapy to isolated tumors and metastatic disease. MSC have been readily engineered to express anti-proliferative, pro-apoptotic, anti-angiogenic agents that specifically target different cancer types. Many of these strategies have been validated in a wide range of studies evaluating treatment feasibility or efficacy, as well as establishing methods for real-time monitoring of stem cell migration in vivo for optimal therapy surveillance and accelerated development. This review aims to provide an in depth status of current MSC-based cancer therapies, as well as the prospects for their clinical translation.
最近的临床前和临床研究表明,基于干细胞的疗法为治疗人类疾病带来了巨大的希望。间充质干细胞(MSC)作为有前途的抗癌药物正在出现,具有巨大的潜力被用于治疗多种不同类型的癌症。MSC 具有固有的肿瘤营养迁移特性,这使它们能够作为载体将有效的靶向治疗传递给孤立的肿瘤和转移性疾病。MSC 已经被容易地设计成表达抗增殖、促凋亡、抗血管生成剂,这些剂专门针对不同类型的癌症。许多这些策略已经在广泛的研究中得到验证,这些研究评估了治疗的可行性或疗效,以及建立了实时监测干细胞在体内迁移的方法,以进行最佳治疗监测和加速开发。这篇综述旨在提供基于 MSC 的癌症治疗的深入现状,以及它们临床转化的前景。